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The comparison of pandemic H1N1 IgG levels between
H1N1 influenza-vaccinated healthcare workers and unvaccinated
healthcare workers
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Background/aim: To compare pandemic H1N1 (pH1N1) IgG antibody levels between healthcare workers who were vaccinated with
the pH1N1 influenza vaccine and the unvaccinated healthcare workers who were selected as the control group.
Materials and methods: A total of 68 healthcare workers were included in this study. Of those, 53 were adults vaccinated with the H1N1
influenza vaccine and 15 were unvaccinated. Serum samples were parsed and stored at –40 °C until they were examined.
Results: Of the total 53 vaccinated healthcare workers, 16 (30.1%) were positive for IgG antibodies (titer > 11), 17 (32.0%) were negative
for IgG antibodies (titer < 9), and 20 (37.7%) were borderline (titer: 9–11). Of the 15 unvaccinated healthcare workers, 1 (6.6%) was
positive for IgG antibodies, 11 (73.3%) were negative for IgG antibodies, and the remaining 3 (20.0%) had borderline values (P = 0.014,
P < 0.05). In both groups, there was no statistically significant difference between IgG-negative, IgG-positive, and borderline subjects
in terms of age or sex.
Conclusion: The IgG antibody level was higher in the vaccinated healthcare workers than among the unvaccinated healthcare workers.
Key words: H1N1 vaccination, healthcare workers, H1N1 IgG antibody level

1. Introduction
Pandemic influenza H1N1 (pH1N1) infection emerged
for the first time in April 2009 in Mexico and spread from
there throughout the world. A total of 128 cases were
reported in Turkey, which were confirmed between May
and July 2009. The only way to terminate a pandemic is
to immunize society. Natural immunity is possible by
contracting the illness. However, vaccines are superior
for creating immunity before contracting the illness (1).
According to data from the Ministry of Health of the
Republic of Turkey, a total of 207,580 health workers have
been immunized with the pH1N1 vaccine.
The purpose of this study was to compare the IgG
antibody levels against the H1N1 virus in 53 healthcare
workers who were vaccinated with the vaccine during the
H1N1 pandemic influenza and 15 healthcare workers,
selected as the control group, who were not vaccinated
with the H1N1 vaccine.
* Correspondence: dr.aydin.71@hotmail.com

2. Materials and methods
A total of 68 healthcare personnel were included in this
study. There were 53 adult healthcare personnel (39 males,
14 females; mean age: 43 years) to whom the H1N1 vaccine
was administered and 15 healthcare personnel (8 males,
7 females; mean age: 45 years) to whom the vaccine was
not administered. The approval of the ethics committee
and patient consent forms from the healthcare personnel
were obtained for the study. Approximately 3 months after
vaccination, blood samples were taken simultaneously
from the healthcare personnel who were vaccinated and
from the healthcare personnel were not vaccinated. Serum
samples were parsed and stored at –40 °C until they were
examined.
The IgG antibody levels against H1N1 influenza
vaccine in the healthcare personnel who were and
were not vaccinated were analyzed with the New
Influenza Commercial Pandemic IgG Original ELISA
Kit (Genzyme Virotech, Germany), in accordance with
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the recommendations of the manufacturer. This study
considered IgG antibody titration of >11 AU (arbitrary
units) to be positive, IgG antibody titration of <9 AU
(arbitrary units) to be negative, and IgG antibody titration
of 9–11 AU (arbitrary units) as a borderline value (http://
www.sekisuivirotech.com).
In the statistical analysis, independent sample t-test
and Pearson chi-square were carried out with SPSS 15.
Values of P < 0.05 were considered statistically significant.
3. Results
Of the 53 vaccinated health personnel, H1N1 IgG
antibodies (titration > 11) were positive in 16 (30.1%),
negative (titration < 9) in 17 (32.0%), and borderline
(titration: 9–11) in 20 (37.7%). Of the 15 healthcare
workers who were not vaccinated, 1 (6.6%) was positive,
11 (73.33%) were negative, and 3 (20.0%) had borderline
values.
There was a statistically significant difference between
the positive, negative, and borderline IgG antibody levels
for those who were vaccinated and those who were not
vaccinated, thus being selected as the control group (P =
0.04, P ≤ 0.05).
The mean antibody levels were detected at 10.63
± 3.39 in the vaccinated group and 8.40 ± 2.11 in the
unvaccinated group. There was a statistically significant
difference between the antibody levels (P = 0.04 and P ≤
0.05, respectively).
In both groups, there was no statistically significant
difference between H1N1 IgG antibody-positive,
antibody-negative, and borderline subjects in terms of age
or sex (P > 0.05).
4. Discussion
Around the world, as well as in Turkey, influenza is an
important health problem, especially in the winter and
autumn seasons. H1N1 influenza, which emerged in
2009, caused a pandemic throughout the world, including
Turkey. An effective vaccination program is the most
economic and practical method to prevent infection from
the influenza virus (1,2).
The target population for the vaccine is considered
to be pregnant women, individuals who became infected
at home, caregivers of children younger than 6 months,
healthcare and emergency service workers, children
between the ages of 6 months to 18 years, adults between
the ages of 19 to 24 years, and individuals between the
ages of 25 and 64 who are at risk for complications from
influenza (2).
In the literature, different data are available on the
effectiveness of the pH1N1 influenza vaccine. In a study
conducted by Simpson et al. (3) in Scotland, it was
reported that the effectiveness of the H1N1 influenza
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vaccine in preventing diseases associated with influenza
in emergency departments was 19.5%, and the laboratoryconfirmed effectiveness of the vaccine in preventing
influenza was 77%.
In a study conducted by Noah et al. (4), in 20 (25.5%)
of 47 HIV-positive patients and in 2 (2.8%) of 71 healthy
individuals, a sufficient IgG antibody response was not
detected after vaccination. Four weeks after vaccination,
the antibody response in healthy subjects and HIV-positive
individuals were 16.8 ± 2.4 virotech units (VU) and 13.8
± 5.3 VU, respectively; the antibody response in healthy
individuals was higher than in HIV-positive patients.
In the study by Dikow et al. (5) performed with 291
patients undergoing hemodialysis, 64 of 169 patients
were vaccinated with a single dose of vaccine and 105
patients were vaccinated with 2 doses of vaccine. The
control group comprised 123 patients who did not accept
vaccination. Pandemic influenza IgG levels in the patient
and control groups were determined by ELISA, and 11
AU was accepted as a positive response. Quantitative IgG
antibody titers were examined 3 months after vaccination
in vaccinated patients and control subjects. In the study, a
protective IgG antibody response developed in 41 (64.1%)
of the 64 patients vaccinated with a single dose of pH1N1
influenza vaccine, in 93 (88.6%) of the 105 patients with 2
doses of vaccine, and in 43 (34.9%) of the 123 patients who
did not receive the vaccine. The antibody response was
higher in the group that received the vaccine compared to
the control group.
In the study of Lagler et al. (6), which evaluated
seroconversion and seroprotection rates of inactivated
H1N1 vaccine in 79 HIV-infected adults by standard
hemagglutination inhibition (HAI) test, the H1N1 IgG
antibody levels were also evaluated via the ELISA method.
Tolerance after vaccination was evaluated 1 month after
the second dose of the vaccine. Initially, it was determined
that, in 55 of 79 patients, HAI was ≥1:40, and IgG positivity
was detected in 2 patients.
The seroconversion rate was 31% after the first vaccine
and increased to 41% after the second vaccine. The
seroprotection rates after the first and second vaccine were
92% and 83%, respectively. ELISA IgG antibody levels after
the first and second vaccine were positive, at 25% and 35%,
respectively. As a result, it was reported that inactivated
H1N1 vaccine in HIV-infected individuals was well
tolerated and generated a measurable immune response.
Although Dikow et al. (5) and Lagler et al. (6) found
H1N1 IgG-antibody positivity rates at about 90% after
vaccination, in our study it was found to be about 30.1%
among the healthcare personnel after vaccination. H1N1
IgG-antibody positivity was found to be about 6.6% among
unvaccinated healthcare personnel. This figure was nearly
4 times less than the figure we found among the vaccinated

ÇİFCİ et al. / Turk J Med Sci
healthcare personnel. No serious adverse effects as a result
of the vaccine were observed, and in 43 (86.4%) of 169
patients, mild or moderate local side effects were observed.
In conclusion, those authors reported that pH1N1adjuvanted vaccine was immunogenic, safe, and effective
in patients undergoing hemodialysis. In the present study,
with the exception of local symptoms such as pain, redness,
and increased temperature, which were observed in a very
small segment of the healthcare personnel after vaccination,
other side effects were not observed.
In a study carried out by Temiz et al. (7) on 70
hemodialysis patients from Turkey, the cut-off value
was regarded as 1.503. The figures above this value were
accepted as positive in terms of preventive antibody levels,
while the figures under this value were accepted as negative.
They found the rates of positivity similar in hemodialysis
patients and in the healthy control group after vaccination
(68/70 = 97.1%, 19/20 = 95%, respectively). These rates
were similar to the findings of Lagler et al. (6) and Dikow
et al. (5). As a result, they decided that H1N1 vaccination
was reliable and effective for hemodialysis patients.
In a nonrandomized observational study conducted
by Meyer et al. (8) on 47 patients that underwent heart
transplantation, antibody titers against an inactivated,
adjuvanted H1N1 vaccine were evaluated using the
HAI test and a pandemic influenza A H1N1 IgG ELISA
kit. Antibody titers measuring 1:40 and higher after
vaccination were detected in 15 patients as positive,
and it was determined that this corresponded to a 32%
seroprotection rate. The sensitivity, specificity, positive
predictive values, and negative predictive values of the
H1N1 influenza IgG ELISA kit used in this study were
80.0%, 68.8%, 54.5%, and 88%, respectively. As a result,
the authors reported that a single dose of inactivated
adjuvanted vaccine caused a considerable proportion
of immunosuppressive antibody response in patients
with heart transplantation and an immunosuppressive
seroprotective antibody response caused by pandemic
H1N1 influenza A.
The IgG commercial kit has limited clinical use. Sayan
et al. (9) observed using ELISA an antihemagglutinin
exchange of antibodies in 50 vaccines in 50 patients with
chronic obstructive pulmonary disease and asthma, who

were vaccinated with the influenza vaccine before the
1994–1995 influenza season, and compared the sensitivity
and specificity of this method with the HAI method. The
seroconversion of IgG antibodies was detected for the
sixth month as 64%, 52%, and 40% for a subtype of H1N1,
subtype of H3N2, and the B-type, respectively, and the
sensitivity and specificity of the ELISA method was 76%
and 88%, respectively. This study revealed that the ELISA
method was time-efficient and relatively sensitive and
specific, and could be used to monitor seroconversion and
infection.
Sun et al. (10), in their study, examined specific
antibody responses after vaccination using the HAI test
and ELISA by analyzing IgG levels in 58 volunteers who
were vaccinated with the pandemic H1N1 vaccine (2009 A/
H1N1). It was reported that protective IgG antibody levels
developed at the earliest within 10 days, and the antibody
response continued for 60 days without a decrease.
As a result, IgG antibody positivity was approximately
30.1% in health personnel vaccinated with the H1N1
vaccine, whereas this rate was 6.6% in healthy individuals
who were not vaccinated. The IgG antibody level was
approximately 4 times higher in patients who were
administered the H1N1 vaccine, compared to individuals
who did not receive the vaccine. However, one limitation
of this study was the fact that borderline (limit-value) IgG
values were obtained in both vaccinated and unvaccinated
individuals and could not be evaluated as positive or
negative. The IgG antibody response against the H1N1
vaccine was determined in medical staff, with the exception
of those with borderline values (between 9 and 11 titers),
as approximately 30%. When the borderline values were
included, this rate was approximately 68%.
The H1N1 IgG ELISA method is a very practical
method to determine the immune response to the H1N1
vaccine compared to the HAI test. The current study is
one of the few studies in Turkey that investigates IgG titers
against the H1N1 vaccine using ELISA.
To exactly determine the importance of IgG response
(humoral immune response) against the H1N1 vaccine,
other controlled studies comparing IgG levels against the
H1N1 influenza virus between vaccinated groups and
individuals who were naturally infected are needed.
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